Results 101 to 110 of about 8,452 (228)

The Clinical, Humanistic, and Economic Burden of Idiopathic Hypersomnia in the United States: Analysis of the National Health and Wellness Survey

Nature and Science of Sleep
Caroleen Drachenberg,1 M Janelle Cambron-Mellott,2 Lin Yang,2 Bridget L Balkaran,2 Marisa Whalen,3 David T Plante4 1Global Value & HEOR, Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Oracle Life Sciences, Oracle Corporation, Austin, TX, USA; 3US Medical
Drachenberg C, Cambron-Mellott MJ, Yang L, Balkaran BL, Whalen M, Plante DT   +5 more
doaj  

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Twórcy polscy w RWE

Archiwum Emigracji, 2009
Rec.: Violetta Wejs-Milewska, Radio Wolna Europa na emigracyjnych szlakach pisarzy.
openaire   +2 more sources

Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance

Journal of Market Access & Health Policy
Background: Real-world evidence (RWE) can reinforce clinical trial evidence in health technology assessment (HTA). Objectives: Review HTA bodies’ (HTAbs) requirements for RWE, real uses, and acceptance across seven countries (Brazil, Canada, France ...
Katia Thokagevistk, Céline Coppo, Laetitia Rey, Amanda Carelli, Veronica Díez, Sarah Vaselenak, Liana Oliveira, Ajay Patel, Emilia Sicari, Teresa Ramos, Susanne Schach, Erika Schirghuber, Alex Simpson, Remy Choquet, Katell Le Lay   +14 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Age diversity - promoting equal opportunities in RWE [PDF]

, 2012
The topic of the thesis entitled "Age diversity - promoting equal opportunities in RWE" is an analysis of diversity management tools specific to the company from 2011 to 2012, defining age management and proposing an action plan of age diversity in the ...
Procházková, Petra
core  

Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8438-8451, September 2026.
ABSTRACT Aims To evaluate the real‐world effectiveness, safety and patient‐reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost‐constrained setting. Methods This 30‐week, prospective, multicentre, non‐interventional study enrolled adults with T2DM initiating ...
Arshad Hussain, Muhammad Umar Wahab, Saleem Qureshi, Umar Yousaf Raja, Atif Munir, Shahnawaz Gardezi, Musarrat Iqbal, Bilal Afzal, Muhammad Daoud Butt, Siew Chin Ong   +9 more
wiley   +1 more source

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Bioengineering
The use of real-world data (RWD) for healthcare decision-making is complicated by concerns regarding whether RWD is fit-for-purpose or is of sufficient validity to support the creation of credible RWE.
Kelly H. Zou, Marc L. Berger
doaj   +1 more source

Clinical Development of Therapies for Charcot–Marie–Tooth Disease: Recommendations for Trial Design, Endpoints, and Regulatory Pathways

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT Charcot–Marie–Tooth disease (CMT) encompasses a heterogeneous group of inherited peripheral neuropathies. Despite being the most common genetic neurological condition, individual CMT subtypes are rare, presenting unique challenges for therapeutic development.
Charles K. Abrams, Sue Bruhn, Joshua Burns, Rebekah Fleming, Katherine Forsey, Vera Fridman, David N. Herrmann, Brian Lin, Susan McCune, Allison Moore, Susan Ruediger, Michael Shy, Shannon Strom, ToPIC:CMT Steering Committee, Shannon Strom, Peggy Allred, Dottie M. Caplan, Samuel Collins, David Goldstein, Christina Greeley, Benit S. Maru, Thomas Holm Pedersen, Terry Pirovolakis, Rachel Salzman, Iris Schultz   +24 more
wiley   +1 more source

Film Thickness Nonuniformity and the Crucial Role of Water Dosage for Atomic Layer Deposition of Yttrium Oxide

physica status solidi (a), Volume 223, Issue 16, 19 August 2026.
To ensure the expected atomic layer deposition (ALD), this work emphasizes the need to (i) combine local growth kinetics analysis with large‐scale thickness nonuniformity assessment approaches and (ii) carefully select the H2O dosage as well as the process temperature applied to the ALD of Y2O3 from (MeCp)3Y and H2O precursors.
Weihua Wu, Robbert W. E. van de Kruijs, Dirk J. Gravesteijn, Z. Silvester Houweling, Giorgio Colombi, Alexey Y. Kovalgin   +5 more
wiley   +1 more source